Radiotherapy + Checkpoint Inhibitor for Kidney Cancer
(SPARK Trial)

Recruiting in Palo Alto (17 mi)

Overseen byRAQUIBUL HANNAN, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: University of Texas Southwestern Medical Center

No Placebo Group

Prior Safety Data

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?To evaluate progression of metastatic renal cell carcinoma from the initiation of PULSAR radiotherapy in combination with IMSA101 injectable onward.

Eligibility Criteria

This trial is for individuals with metastatic renal cell carcinoma, a type of kidney cancer that has spread to other parts of the body. Specific eligibility criteria are not provided, so it's important to contact the study organizers for detailed requirements.

Inclusion Criteria

My cancer has spread to 3 or fewer places.

My organ and bone marrow functions are within normal ranges.

All IMDC risk categories are allowed

+5 more

Exclusion Criteria

My cancer has not spread to the center of my chest.

Participant Groups

The trial is testing the effectiveness of PULSAR radiotherapy when combined with an injectable treatment called IMSA101 in slowing down or stopping the progression of metastatic kidney cancer.

1Treatment groups

Experimental Treatment

Group I: SAbR with Intratumoral STING agonist IMSA101 and IO with Anti-PD1Experimental Treatment1 Intervention

Only one arm will be maintained in this phase II study with all patients undergoing the following treatment: SOC treatment: Nivolumab 480 mg monthly PULSAR: 36 Gy in 3 fractions, Q4weeks IMSA101: five intra-tumoral injections of one of the progressive lesions at 1200 mcg (C1D1, C1D8, C1D15, C2D1, C3D1)